前列腺癌合并心血管病患者接受GnRH激动剂或拮抗剂时的心脏生物标志物
该研究为一项II期随机研究的回顾性分析,纳入80例有心血管疾病史的前列腺癌患者,接受GnRH激动剂或拮抗剂治疗。基线NTproBNP(p=0.008)和hsTn(p=0.004)升高与GnRH激动剂组新发心血管事件相关,而拮抗剂组无此关联。作者认为心脏生物标志物作为ADT患者心血管风险预测工具值得进一步研究,但样本量小需更大研究验证。
要点
- 基线NTproBNP和hsTn升高与GnRH激动剂组新发心血管事件相关
- GnRH拮抗剂组未观察到上述生物标志物与心血管事件的关联
- 心脏生物标志物预测ADT心血管风险需更大样本验证
核心结论
- 在有心血管疾病史的前列腺癌患者中,基线NTproBNP和hsTn升高与GnRH激动剂治疗期间新发心血管事件相关,但与拮抗剂无关。
研究设计与样本
- 对一项前瞻性评估心血管事件的II期随机研究进行事后分析,共80例有心血管疾病史的前列腺癌患者接受GnRH激动剂或拮抗剂治疗。
- 采用Cox比例风险模型分析基线及12个月治疗期间所选生物标志物对心血管事件的预测作用。
主要发现
- 基线NTproBNP高水平(p=0.008)和hsTn高水平(p=0.004)与GnRH激动剂组新发心血管事件相关。
- GnRH拮抗剂组未发现基线NTproBNP或hsTn与新发心血管事件的相关性。
- GnRH激动剂组中,NTproBNP随时间升高与新发心血管事件呈非显著趋势。
关键数值与推荐
- 基线NTproBNP与GnRH激动剂组新发心血管事件相关,p=0.008。
- 基线hsTn与GnRH激动剂组新发心血管事件相关,p=0.004。
临床怎么用
- 对于有心血管疾病史并计划接受GnRH激动剂治疗的前列腺癌患者,可考虑检测基线NTproBNP和hsTn以辅助心血管风险评估。
局限性
- 样本量小(80例),需更大规模研究验证生物标志物在ADT患者中预测心血管事件的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gonadotrophin releasing hormone (GnRH) agonists and antagonists reduce testosterone levels for the treatment of advanced and metastatic prostate cancer. Androgen deprivation therapy (ADT) is associated with increased risk of cardiovascular (CV) events and CV disease (CVD), especially in patients with preexisting CVD treated with GnRH agonists. Here, we investigated the potential relationship between serum levels of the cardiac biomarkers N-terminal pro-B-type natriuretic peptide (NTproBNP), D-dimer, C-reactive protein (CRP), and high-sensitivity troponin (hsTn) and the risk of new CV events in prostate cancer patients with a history of CVD receiving a GnRH agonist or antagonist. METHODS: Post-hoc analyses were performed of a phase II randomized study that prospectively assessed CV events in patients with prostate cancer and preexisting CVD, receiving GnRH agonist or antagonist. Cox proportional hazards models were used to determine whether the selected biomarkers had any predictive effect on CV events at baseline and across a 12-month treatment period. RESULTS: Baseline and disease characteristics of the 80 patients who took part in the study were well balanced between treatment arms. Ischemic heart disease (66%) and myocardial infarction (37%) were the most common prior CVD and the majority (92%) of patients received CV medication. We found that high levels of NTproBNP (p = 0.008), and hsTn (p = 0.004) at baseline were associated with the development of new CV events in the GnRH agonist group but not in the antagonist. In addition, a nonsignificant trend was observed between higher levels of NTproBNP over time and the development of new CV events in the GnRH agonist group. CONCLUSIONS: The use of cardiac biomarkers may be worthy of further study as tools in the prediction of CV risk in prostate cancer patients receiving ADT. Analysis was limited by the small sample size; larger studies are required to validate biomarker use to predict CV events among patients receiving ADT.
引用
- Margel D, Ber Y, Peer A, et al. Cardiac biomarkers in patients with prostate cancer and cardiovascular disease receiving gonadotrophin releasing hormone agonist vs antagonist. Prostate Cancer Prostatic Dis. 2020. PMID: 32737420. doi:10.1038/s41391-020-0264-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。